Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has issued a notice convening its 2025 Annual General Meeting (AGM) for 26 June 2026 at 14:00 (Room 302, Building 4, No. 590 Ruiqing Road, Pudong, Shanghai).
Key resolutions to be tabled are as follows:
1. 2025 Operating Reports • Board and Board of Supervisors will present separate work reports for the year. • Audited consolidated financial statements and the 2025 annual report will be submitted for approval.
2. 2025 Profit Distribution Plan • Shareholders will vote on the proposed profit distribution; details have not been disclosed in this notice.
3. Auditor Re-appointment • Ernst & Young Hua Ming LLP (domestic) and Ernst & Young (international) are nominated for re-appointment until the next AGM, with remuneration to be set by the Board.
4. Board Composition • Six directors are up for re-election to the third Board session: – Executive Directors: Philip Li Wang, Yunqing Wang, Peili Wang – Independent Non-executive Directors: Yiqing Chen, Xubo Lu, Yifei Jiang
5. Corporate Governance Updates • Amendments to the Rules of Procedure for the Board of Directors and for Shareholders’ General Meetings will be considered. • Shareholders will vote on abolishing the current Board of Supervisors. • Adoption of a new amended and restated Articles of Association is proposed, with authorization for any director to complete related formalities.
6. General Mandate for Share Issuance • The Board seeks authority, during the period ending at the next AGM or 12 months from approval (whichever is earlier), to issue up to: – 20% of existing H-shares (excluding treasury shares) and/or – 20% of existing unlisted foreign shares. • The mandate includes the power to determine issuance terms, execute documentation, and amend the Articles of Association to reflect any capital changes, subject to regulatory approvals.
Administrative Details • The H-share register closes 15–26 June 2026; shareholders must lodge transfers by 16:30 on 12 June 2026 to qualify for attendance and voting rights. • Proxy forms must reach Computershare Hong Kong Investor Services or the Company’s registered office by 14:00 on 25 June 2026. • All AGM resolutions will be decided by poll.
Leadership and Contact • Board: Executive Directors – Philip Li Wang (Chairman), Yunqing Wang, Peili Wang; Independent Non-executive Directors – Yiqing Chen, Xubo Lu, Yifei Jiang. • Registered office: Room 302, 3/F, Building 4, No. 590 Ruiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai. • Enquiries: Tel. +86 21 6879 8511; Email info@bio-heart.com